BSLN: Strong revenue growth, robust pipeline, and global leadership in anti-infectives drive future expansion
A profitable Swiss biopharma with a capital-efficient model, strong global partnerships, and a focus on anti-infectives, is driving growth through its leading brands Cresemba and Zevtera, a robust late-stage pipeline, and significant non-dilutive funding. FY 2025 saw strong revenue and profit, with…